Search Result

Results for "

UCP1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Anion Exchangers (1) AP-1 (2) ATP Synthase (1) Bacterial (1) c-Myc (1) Carboxylesterase (CES) (1) Caspase (2) CDK (2) Collagen (1) COX (1) Drug Metabolite (1) Endogenous Metabolite (1) Fatty Acid Synthase (FASN) (1) HDAC (1) Histone Methyltransferase (2) iGluR (2) JNK (1) Keap1-Nrf2 (2) Mitochondrial Metabolism (3) NF-κB (3) Nuclear Hormone Receptor 4A/NR4A (1) p38 MAPK (1) PGC-1α (4) PKA (2) PPAR (3) Progesterone Receptor (1) Reference Standards (4) Sirtuin (2) Small Interfering RNA (siRNA) (3) STAT (1) TGF-β Receptor (1) α-synuclein (1)
By Research Areas:	Cancer (6) Endocrinology (1) Infection (2) Inflammation/Immunology (9) Metabolic Disease (19) Neurological Disease (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Natural
Products

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0704

Agrimol B 1 Publications Verification	Sirtuin PPAR Fatty Acid Synthase (FASN) c-Myc Bacterial	Infection Metabolic Disease Cancer
Agrimol B, a polyphenol, is an orally active and potent *SIRT1* activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, *UCP-1, and apoE* expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27 ^[1] .

HY-107574

TC-E 5003 3 Publications Verification	Histone Methyltransferase AP-1 NF-κB PKA	Metabolic Disease Inflammation/Immunology Cancer
TC-E 5003 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC₅₀ of 1.5 µM against hPRMT1. TC-E 5003 modulates the lipopolysaccharide (LPS) (HY-D1056)-induced AP-1 and NF-κB signaling pathways with anti-inflammatory properties. TC-E 5003 also upregulates the expression of Ucp1 and Fgf21, activates protein kinase A signaling and lipolysis in primary subcutaneous adipocytes from both mouse and humans. TC-E 5003 is promising for research of obesity and associated metabolic disorders, oxidative stress, inflammation and cancers ^[1] .

HY-P2917

Glycerol kinase, microorganism GyK	Nuclear Hormone Receptor 4A/NR4A	Metabolic Disease Inflammation/Immunology
Glycerol kinase, microorganism (GyK) acts as a *NR4A1* inhibitor with enzymatic activity. It directly binds to and inhibits the transcription factor NR4A1, thereby negatively regulating hepatic gluconeogenesis and reducing blood glucose levels. Glycerol kinase, microorganism positively regulates *UCP1* expression via partial dependence on the β-adrenergic receptor-cAMP-CREB pathway, promotes browning of white adipose tissue and thermogenesis, and further modulates intracellular fatty acid composition and energy metabolism. In diabetic mouse models, overexpression of Glycerol kinase effectively antagonizes NR4A1-induced hyperglycemia, demonstrating potential for improving glucose homeostasis. Glycerol kinase, microorganism can be used for studies on diabetes and obesity ^[1] .

HY-N0260

Epmedin C Maximum Cited Publications 6 Publications Verification Epimedin-C; Baohuoside-VI	Keap1-Nrf2 CDK Caspase	Infection Metabolic Disease Inflammation/Immunology Cancer
Epmedin C (Epimedin-C; Baohuoside-VI) is an orally active anti-inflammatory agent and immunomodulator that binds to multiple key proteins including UCP1, Caspase-1, CDK2 and *Keap1. Epmedin C inhibits epithelial cell proliferation by disrupting the complex function of CDK2/Cyclin E. Epmedin C also upregulates Nrf2* expression, reduces ROS levels and inhibits pro-inflammatory cytokine secretion, thereby effectively restoring antibody production and alleviating tissue damage. Epmedin C has good safety with no hepatotoxicity or skin sensitization, and it has been used in studies on diseases such as obesity, Deoxynivalenol (HY-N6684)-induced immunotoxicity and mammary hyperplasia ^[1] .

HY-138207

N-Oleoyl-L-phenylalanine	Mitochondrial Metabolism Drug Metabolite	Inflammation/Immunology
N-Oleoyl-L-phenylalanine is a long-chain N-acyl-L-phenylalanine and also a mitochondrial uncoupler. N-Oleoyl-L-phenylalanine uncouples *UCP1*-independent respiration in mitochondria, thereby helping to regulate glucose homeostasis. As an endogenous metabolite, the level of N-Oleoyl-L-phenylalanine increases in patients with ulcerative colitis after a high-fat diet. N-Oleoyl-L-phenylalanine can be used in studies related to ulcerative colitis ^[1] .

HY-129692

Withanone 1 Publications Verification	iGluR	Neurological Disease Cancer
Withanone is an active ingredient from the roots of Withania somnifera and a GRP75 inhibitor. Withanone has multifunctional neuroprotective effects in alleviating cognitive dysfunction. In neuron-like cells, Withanone can inhibit NMDA-induced excitotoxicity. Withanone can inhibit white adipose tissue browning by blocking the formation of the *GRP75-ANT2-UCP1* complex, thereby alleviating cancer-related cachexia. Withanone can be used in the research of tumors and nervous system diseases ^[1] .

HY-114557

NSC 90469 3,5-Diiodo-L-thyronine	JNK NF-κB Sirtuin PGC-1α COX TGF-β Receptor Collagen	Metabolic Disease Inflammation/Immunology Endocrinology
NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks *SIRT1* protein expression, induces elevated *PGC-1α* levels, and stimulates COX activity. NSC 90469 enhances *UCP1*-mediated thermogenesis, increases hepatic *Dio1* activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases *TGF-β1* expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity ^[1] .

HY-135115

Oleuropein Aglycone 3,4-DHPEA-EA	α-synuclein HDAC Adrenergic Receptor	Inflammation/Immunology
Oleuropein Aglycone (3,4-DHPEA-EA) is a polyphenol and the aglycone form of oleuropein (HY-N0292), formed by enzymatic, acidic or acetylated hydrolysis of oleuropein. Dietary intake of oleuropein Aglycone (50 mg/kg diet) increases the number of neuronal autophagic vesicles, reverses cognitive deficits in the TgCRND8 transgenic mouse model of Alzheimer's disease, and reduces the levels of histone deacetylase 2 (HDAC2) in the cortex and hippocampus. Oleuropein Aglycone increases urinary norepinephrine, interscapular brown adipose tissue epinephrine, and UCP1 protein levels, and reduced plasma leptin levels and total abdominal adipose tissue weight in a rat model of high-fat diet-induced obesity. Oleuropein Aglycone also reduced lung neutrophil infiltration, lipid peroxidation, and *IL-1β* levels in a mouse model of carrageenan-induced pleurisy.

HY-110148

WWL113	Carboxylesterase (CES)	Metabolic Disease
WWL113 is a selective and orally active Ces3 and *Ces1f* inhibitor, with IC₅₀ values of 120 nM and 100 nM for Ces3 and Ces1f, respectively. WWL113 appears to show excellent selectivity for the 60-kDa serine hydrolase (or hydrolases) ^[1].

HY-RS16955

Ucp1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Metabolic Disease
Ucp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ucp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ucp1 Mouse Pre-designed siRNA Set A Ucp1 Mouse Pre-designed siRNA Set A

HY-153813

Z16078526	p38 MAPK Mitochondrial Metabolism	Others
Z16078526 induces endogenous Ucp1 expression, promotes p38 MAPK phosphorylation and lipolysis in primary mouse brown adipocytes. Z16078526 activates thermogenic gene expression and mitochondrial activity (uncoupled respiration) in mouse brown adipocytes. Z16078526 also stimulates thermogenesis in the mouse ^[1].

HY-133095

BML-260	STAT PPAR	Inflammation/Immunology
BML-260 is a potent inhibitor of dual-specific phosphatases *JSP-1* and DUSP22. BML-260 can activate UCP1 and thermogenesis in adipocytes in a *JSP-1*-independent manner. The effect of BML-260 on adipocytes is partially achieved through the activation of CREB, STAT3, and PPAR signaling pathways. BML-260 can be used in the research of inflammatory and proliferative disorders associated with JNK signaling dysfunction as well as obesity ^[1] .

HY-RS15410

UCP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
UCP1 Human Pre-designed siRNA Set A contains three designed siRNAs for UCP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

UCP1 Human Pre-designed siRNA Set A UCP1 Human Pre-designed siRNA Set A

HY-RS23398

Ucp1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ucp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ucp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ucp1 Rat Pre-designed siRNA Set A Ucp1 Rat Pre-designed siRNA Set A

HY-148973

ZW290	ATP Synthase	Metabolic Disease
ZW290 is a compound to activate brown adipose tissue (BAT) thermogenic function. ZW290 increases the expression of uncoupling Protein 1 (UCP1) protein and inhibits ATP synthesis in BAT ^[1].

HY-153812

AST 7062601 AST070	Anion Exchangers	Metabolic Disease
AST 7062601 (AST070) is a *Ucp1* inducer that strongly induces endogenous Ucp1 expression in primary mouse brown adipocytes. Ucp1 refers to uncoupling protein, found in brown and beige fat cells. In mammals, UCP1 oxidizes fatty acids and uncouples ATP production in mitochondria to promote energy dissipation as heat. AST 7062601 can be used to study thermogenic, uncoupled respiration ^[1].

HY-176148

ZGL-18	Mitochondrial Metabolism	Metabolic Disease
ZGL-18 is an uncoupling protein 1 (UCP1)-inspired mitochondrial uncoupler. ZGL-18 activates brown adipocytes and reduces mitochondrial membrane potential ^[1].

HY-101824

NC-2100	PPAR	Metabolic Disease
NC-2100 is a PPAR activator. NC-2100 can effectively reduce the plasma glucose and triglyceride levels of obese KKAy mice. NC-2100 can induce *UCP1* and *UCP2* expression in mesenteric and subcutaneous WAT of mice. NC-2100 can be used in research related to type 2 diabetes ^[1].

HY-129692R

Withanone (Standard)	Reference Standards iGluR	Neurological Disease Cancer
Withanone (Standard) is the analytical standard of Withanone (HY-129692). This product is intended for research and analytical applications. Withanone is an active ingredient from the roots of Withania somnifera and a GRP75 inhibitor. Withanone has multifunctional neuroprotective effects in alleviating cognitive dysfunction. In neuron-like cells, Withanone can inhibit NMDA-induced excitotoxicity. Withanone can inhibit white adipose tissue browning by blocking the formation of the *GRP75-ANT2-UCP1* complex, thereby alleviating cancer-related cachexia. Withanone can be used in the research of tumors and nervous system diseases ^[1] .

HY-11032

SM-350300	Others	Metabolic Disease
SM-350300 is a glucoprotein. SM-350300 stimulates lipolysis in white adipocytes by activating the cyclic AMP (cAMP) pathway, and upregulates the expression of lipolytic enzymes and uncoupling proteins (UCP1, UCP3) in brown adipose tissue (BAT) and white adipose tissue (WAT). SM-350300 reduces body weight by decreasing carcass fat while increasing lean muscle mass in metabolic disorder models. SM-350300 can be used for the study of metabolic disorders including obesity, type 2 diabetes, and cachexia ^[1].

HY-N0260R

Epmedin C (Standard) Epimedin-C (Standard); Baohuoside-VI (Standard)	Reference Standards Keap1-Nrf2 CDK Caspase	Inflammation/Immunology
Epmedin C (Standard) is the analytical standard of Epmedin C. This product is intended for research and analytical applications. Epmedin C (Epimedin-C; Baohuoside-VI) is an orally active anti-inflammatory agent and immunomodulator that binds to multiple key proteins including UCP1, Caspase-1, CDK2 and *Keap1. Epmedin C inhibits epithelial cell proliferation by disrupting the complex function of CDK2/Cyclin E. Epmedin C also upregulates Nrf2* expression, reduces ROS levels and inhibits pro-inflammatory cytokine secretion, thereby effectively restoring antibody production and alleviating tissue damage. Epmedin C has good safety with no hepatotoxicity or skin sensitization, and it has been used in studies on diseases such as obesity, Deoxynivalenol (HY-N6684)-induced immunotoxicity and mammary hyperplasia ^[1] .

HY-114557R

NSC 90469 (Standard) 3,5-Diiodo-L-thyronine (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
NSC 90469 (Standard) is the analytical standard of NSC 90469. This product is intended for research and analytical applications. NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks *SIRT1* protein expression, induces elevated *PGC-1α* levels, and stimulates COX activity. NSC 90469 enhances *UCP1*-mediated thermogenesis, increases hepatic *Dio1* activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases *TGF-β1* expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity ^[1] .

HY-183097

AM89	PGC-1α	Metabolic Disease
AM89 is a *PGC-1α1* stabilizer. AM89 activates the expression of *PGC-1α1* target genes and induces the upregulation of *Ucp1* gene expression. AM89 is applicable for the research of obesity and related metabolic disorders ^[1].

HY-183095

AM79		Metabolic Disease
AM79 is a *PGC-1α1* stabilizer. AM79 promotes the accumulation of endogenous PGC-1α1 protein, thereby activating its target genes. AM79 increases uncoupled mitochondrial respiration in brown adipocytes. AM79 induces the expression of Ucp1 and Cidea in brown adipocytes. AM79 can be used for the research of obesity and related metabolic disorders ^[1].

HY-183096

AM31	PGC-1α	Metabolic Disease
AM31 is a *PGC-1α1* stabilizer. AM31 enhances the protein stability of *PGC-1α1, promotes protein accumulation and target gene activation. AM31 induces the expression of Ucp1* and Cidea in brown adipocytes. AM31 increases the levels of basal mitochondrial respiration and uncoupled respiration in brown adipocytes. AM31 can be used for the research of obesity and related metabolic disorders ^[1].

HY-183094

AM73	PGC-1α	Metabolic Disease
AM73 is a *PGC-1α1* stabilizer. AM73 increases the expression levels of *Ucp1* and Cidea in brown adipocytes, and enhances basal mitochondrial respiration and uncoupled respiration. AM73 regulates hypoxia, brown adipocyte differentiation, carbohydrate metabolism and insulin signaling pathways in brown adipocytes. AM73 alters the thermogenic process of white adipocytes. AM73 is applicable to the research of obesity and related metabolic disorders ^[1].

HY-107574R

TC-E 5003 (Standard)	Reference Standards Histone Methyltransferase AP-1 NF-κB PKA	Metabolic Disease Inflammation/Immunology Cancer
TC-E 5003 (Standard) is the analytical standard of TC-E 5003 (HY-107574). This product is intended for research and analytical applications. TC-E 5003 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC₅₀ of 1.5 µM against hPRMT1. TC-E 5003 modulates the lipopolysaccharide (LPS) (HY-D1056)-induced AP-1 and NF-κB signaling pathways with anti-inflammatory properties. TC-E 5003 also upregulates the expression of Ucp1 and Fgf21, activates protein K_inase A signaling and lipolysis in primary subcutaneous adipocytes from both mouse and humans. TC-E 5003 is promising for research of obesity and associated metabolic disorders, oxidative stress, inflammation and cancers ^[1] .

HY-186011

CPAG-1	Progesterone Receptor	Metabolic Disease
CPAG-1 is a small-molecule activator of progesterone receptor membrane component 2 (PGRMC2). CPAG-1 can enhance mitochondrial heme delivery to the nucleus mediated by PGRMC2 and activate genes related to heat production in brown adipose tissue (BAT), such as Ucp1 and Pgc-1α, and reduce lipid accumulation in BAT. CPAG-1 reduce fasting blood sugar and insulin levels, and improve glucose tolerance and insulin sensitivity. CPAG-1 can be used for research of type 2 diabetes ^[1].

Cat. No.	Product Name	Target	Research Area